Key Points The company's key drug continues to demonstrate it can produce rapid weight loss in people with obesity. The maintenance dosing data support its potential to generate sustained weight loss for patients. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) stock surged this week on results from a maintenance study of its key pipeline obesity treatment, VK2735. The top-line results led to a slew of Wall Street upgrades and helped support the case for VK2735 as a potential long-term obesity treatment, and the company promptly announced a $400 million capital raise, which it increased to $500 million the following day.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。